Henglee (Legacy) / Specialty Asset (HNGE)

Hinge Health, Inc. (HNGE) is the pioneer and leader in digital musculoskeletal (MSK) clinic technology, headquartered in San Francisco, California. Led by Co-founder and CEO Daniel Perez, Hinge Health’s strategic mission is to "automate healthcare delivery and make high-quality MSK care accessible to everyone, everywhere." The company holds a dominant industry position, serving over 2,300 self-insured employers and health plans as the "Digital Front Door" for joint and muscle pain. The company’s vision is to replace surgery and opioids with evidence-based digital physical therapy and AI-powered care. In late 2025, HNGE stock has been a standout since its highly anticipated IPO in May 2025, with the HNGE stock price reflecting a massive 55% year-over-year revenue growth to $139 million in Q2 alone.

The business operations of Hinge Health utilize an "AI-Powered Care Model" that combines wearable sensors, computer vision, and a dedicated team of clinicians. In fiscal 2025, the company achieved a major financial milestone by reaching positive non-GAAP income from operations, with full-year revenue guidance between $548 million and $552 million. A primary growth driver is the "Total Joint Replacement" program, which has demonstrated a 58% reduction in surgery rates for its members, providing a massive ROI for employers. The 2026 strategic roadmap focuses on "The Agentic Clinician," using generative AI to automate patient feedback and personalization, allowing each physical therapist to manage 5x more members. Hinge Health holds a "Clinical Validation Moat," supported by over 20 peer-reviewed studies proving that its digital-first approach is as effective as in-person therapy. With $415 million in liquidity as of late 2025, HNGE stock is the definitive leader in the multi-billion dollar digital health category.

Hinge Health, Inc. (HNGE) is listed on the New York Stock Exchange (NYSE). For investors researching HNGE stock, the company’s 70% GAAP gross margins and its shift toward a profitable SaaS-like model are key differentiators from other telehealth players. The HNGE stock price is a primary indicator for the adoption of "Value-Based Care" in the employer-sponsored market. For those tracking HNGE stock, the company’s ability to scale its "Enso" wearable technology—which provides non-invasive pain relief—is a major catalyst for future member retention and growth.